<DOC>
	<DOC>NCT01482884</DOC>
	<brief_summary>The study is designed to evaluate the clinical efficacy and safety of tralokinumab as compared to placebo. Investigational product will be administered as subcutaneous injection. All patients will continue background therapy for ulcerative colitis as per local standards of care in addition to investigational product.</brief_summary>
	<brief_title>Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis</brief_title>
	<detailed_description>A phase IIa, randomised, double-blind, placebo-controlled, parallel-arm, multicenter study to evaluate the efficacy and safety of tralokinumab (CAT-354), a recombinant human monoclonal antibody directed against interleukin-13 (IL-13), as add-on therapy, on clinical response in patients with active, moderate-to-severe, ulcerative colitis</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Diagnosed ulcerative colitis at least 90 days prior randomisation. Men or women age 18 75 years. Nonhospitalized patients with moderatesevere ulcerative colitis treated with stable background UC therapy (e.g. containing 5aminosalicylates, and/or low dose of glucocorticosteroids, and/or purine analogue) prior to randomization. Females of childbearing potential who are sexually active with a nonsterilized male partner must use highly effective contraception from Day1. Nonsterilized males or sterilized males who are â‰¤1 year postvasectomy who are sexually active with a female partner of childbearing potential must use a highly effective method of contraception. Pregnant or breastfeeding women. History of colostomy. Current diagnosis of indeterminate colitis, Crohn's disease, ischemic colitis, fulminant colitis and/or toxic megacolon and patients with ulcerative colitis limited to the rectum (ulcerative proctitis). Hepatitis B, C or HIV. History of cancer.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>tralokinumab</keyword>
	<keyword>inflammatory bowel disease</keyword>
	<keyword>moderate to severe ulcerative colitis</keyword>
</DOC>